Aspen Pharmacare shares see a sharp decline on the JSE following an alarming profit warning. What does it mean for investors?
You must be a subscriber to access all of this content.
Adcock Ingram reports steady annual profits as winter demand for Panado and Corenza-C drives growth in the second half.
You must be a subscriber to access all of this content.
The recent R15.5 billion ARV tender sidelines Pharma Giants in South Africa, raising questions about local production support.
You must be a subscriber to access all of this content.
Urgent public health reform is needed to protect vulnerable populations from being denied healthcare in South Africa's public facilities.
You must be a subscriber to access all of this content.
Discover the paradox of TB deaths in South Africa as new infections decline but mortality remains high. Learn more here.
You must be a subscriber to access all of this content.